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Abstract
Background: The macrolid antibiotic tylosin has been widely used to treat canine chronic diarrhea, although its
efficacy is based on anecdotal reports and experimental studies in dogs and not on strong scientific evidence.
The term tylosin-responsive diarrhea (TRD) refers to diarrheal disorders responding to tylosin therapy within a
few days. In TRD, the stool remains normal as long as tylosin treatment continues, but diarrhea reappears in
many dogs within weeks after discontinuation. The aim of our trial was to assess the effect of tylosin on fecal
consistency compared with a placebo treatment in dogs with suspected TRD and additionally to establish
whether tylosin in dogs with recurrent diarrhea is as effective as empirical studies and anecdotal reports
suggest.
Methods: Subjects comprised 71 client-owned dogs that, according to the owners, had previously been
treated successfully with tylosin due to recurrent diarrhea of unknown etiology. At the initial examination,
where there were no signs of diarrhea, the dogs were randomly assigned in a 2:1 ratio to a tylosin or
placebo group. During a two-month follow-up the owners evaluated the fecal consistency according to
previously published guidelines. When diarrhea recurred, either tylosin (25 mg/kg q 24 h, 7 days) or placebo
treatment was initiated orally. Treatment outcome was evaluated as the mean of fecal consistency scores
assigned during the last three days of the treatment period. To test for differences between the tylosin and
placebo group in the proportion of responders, Pearson’s Chi-squared test and Fisher’s exact test were
applied.
Results: Sixty-one dogs met the selection criteria and were followed for two months. During the follow-up 27
dogs developed diarrhea and either tylosin or placebo treatment was started. The proportion of dogs with normal
fecal consistency at the end of treatment was 85% (17/20) in the tylosin group and 29% (2/7) in the placebo
group (Pearson’s Chi-squared test p = 0.0049 and Fisher’s exact test two-sided, p = 0.0114).
Conclusions: Our findings indicate that tylosin is effective in treating recurrent diarrhea in dogs. The dose of 25
mg/kg once daily appears sufficient. No changes specific to TRD were detected in the examinations.
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The macrolid antibiotic tylosin, launched on the drug
market in Finland already 40 years ago in tablet form
under the trade name Tylan
®, was marketed as a useful
medicine for the treatment of different bacterial infec-
tions in dogs. Finnish veterinarians noted that tylosin
was an effective drug in the treatment of canine diar-
rhea. About ten years ago, the tablet form of the drug
was recalled, as the manufacturer was interested mainly
in marketing tylosin in powder form for pigs and poul-
try. Since then, the University Pharmacy in Finland has
dispensed tylosin in tablet form on request, commonly
to treat canine diarrheal disorders. However, usage has
been based on anecdotal reports of owners, rather than
on strong scientific evidence. Recently, the effect of tylo-
sin was shown to differ from that of other antibiotics,
and the term tylosin-responsive diarrhea (TRD) was
proposed for diarrheal disorders responding to tylosin
therapy within a few days [1,2]. In TRD dogs, stool is
normal as long as treatment continues, but diarrhea
reappears in many dogs within weeks after discontinua-
tion [1]. The owners of the dogs reported that even
after several treatments the effect of tylosin was as good
as at the initial treatment. This is astonishing, as tylosin
is an antibiotic substance, and long-term usage of anti-
biotics generally contributes to the development of
microbial resistance. Usually, achieving a positive anti-
biotic treatment is even more difficult if the same anti-
biotic is used repeatedly to treat the same disease in the
same individual.
However, these noncontrolled studies [1,2] were con-
ducted with only a small number of dogs, and whether
tylosin is really as effective as suggested is uncertain.
The diarrhea might resolve by itself, as we know that in
chronic diarrhea patients the symptoms are often fluctu-
ating, and these patients may become temporarily
asymptomatic without any treatment [3]. To close the
gap between empirical studies and evidence-based medi-
cine, we performed a placebo-controlled, randomized,
double-blinded, prospective clinical trial. The aims were
to assess the effect of tylosin on fecal consistency com-
pared with a placebo treatment in dogs with suspected
TRD and to establish whether tylosin treatment in
canine patients with recurrent diarrhea is as effective as
noncontrolled studies and anecdotal reports suggest.
Methods
Over the period of October 2006 and April 2008, 71 cli-
ent-owned dogs with recurrent diarrhea were referred to
the trial at the Small Animal Hospital, Faculty of Veter-
inary Medicine, University of Helsinki, Finland. The
owners signed a written informed consent in which they
agreed to let their dog participate and gave permission
for collection of blood and fecal samples and perfor-
mance of a gastroduodenoscopy on their dogs. The
study protocol (Figure 1) was approved by both the
National Animal Ethics Committee in Finland and the
Ethics Committee for Animal Experiments of the Uni-
versity of Helsinki, Finland.
Selection criteria
One selection criterion was a previous successful
empiric tylosin treatment of the dog for recurrent diar-
rhea of unknown etiology. Suspected TRD dogs were
over six months old and had not been treated with sys-
temic corticosteroids, nonsteroidal anti-inflammatory
drugs, or antibiotics other than tylosin in the 30 days
preceding the trial. At the initial examination, the dogs
were either on current tylosin medication or the tylosin
treatment had been discontinued within the last four
weeks. Pregnant and lactating females were excluded, as
were dogs with evidence of clinically important systemic
or organ-related disease that secondarily could cause
diarrhea. The dogs had no clinical signs of diarrhea at
the initial examination.
Initial examination
At the initial examination, the dogs were randomly
allocated to two treatment groups. A block randomiza-
tion with a block size of 15 was utilized. According to
a skewed randomization, within each block two-thirds
of dogs were assigned to the tylosin group and one-
third to the placebo group, receiving, respectively,
either tylosin tartrate tablets at a dose of 25 mg/kg or
microcrystalline cellulose tablets orally once a day for
seven days. To ensure fulfillment of the selection cri-
teria, the initial examination was performed as follows.
A clinical history and physical examination were car-
ried out. Blood samples were collected for determina-
tion of complete blood count (CBC), serum alanine
transaminase and alkaline phosphatase activities, and
urea, creatinine, glucose, total protein, albumin,
sodium, potassium, cobalamin, folate, and trypsin-like
immunoreactivity concentrations. Urinalysis for specific
gravity, dipstick, and sediment was performed. Fecal
samples from three consecutive days were analyzed for
endoparasite ova using the magnesium-sulfate flotation
method. A fresh fecal sample collected manually from
the rectum was stored at -20°C and examined by a
solid-phase immunoassay (ProSpecT Giardia Micro-
plate Assay, Remel Europe Ltd., Dartford, United King-
dom) for the detection of Giardia spp. The Central
Laboratory of the Department of Equine and Small
Animal Medicine carried out all the analyses for rou-
tine CBC and serum parameters, urinalysis and the
parasitological analyses of the fecal samples. The
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and hematology analyzers. Serum samples of serum
TLI, folate, and cobalamin concentrations were sent
for analysis to a commercial laboratory (Vetlab Oy,
Tampere, Finland).
Dogs with cobalamin concentrations under the refer-
ence range were treated with subcutaneous injections of
cobalamin after release from the trial.
Gastroduodenoscopy was performed and six mucosal
biopsy specimens were obtained from the duodenum. A
histopathological examination of the biopsies was per-
formed by a single European College of Veterinary
Pathology board-certified pathologist. The biopsies were
examined for severity and type of inflammation accord-
ing to the World Small Animal Veterinary Association
(WSAVA) Gastrointestinal Standardization Group`s
international standards [4,5]. Severity of inflammation
was graded as none, mild, moderate, or severe, and type
of inflammation as none, lymphoplasmacytic, eosinophi-
lic, or other.
Follow-up period
Directly after the initial examination, all dogs were trea-
ted with fenbendazole 50 mg/kg once a day for three
days.
Ten days after the initial examination, a follow-up per-
iod of a maximum of two months commenced to deter-
mine whether diarrhea would appear. Tylosin
medication was discontinued in the dogs receiving it at
the time of the initial examination. Throughout the
study, the feeding management and diet of all dogs
remained unchanged from those at the initial
examination.
The owners evaluated and recorded the fecal consis-
tency of each stool specimen according to previously
published guidelines using a nine-point scale, from one
to five, with half-point intervals [1,2,6]. Instructions on
how to evaluate consistency were provided to owners in
both picture and written form to facilitate and standar-
dize the subjective evaluation as far as possible. The
photos were explicit, enabling owners to evaluate the
Figure 1 Study protocol including enrollment, allocation to treatment groups, and treatment of suspected TRD dogs.
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sidered unacceptable. Score 4 feces were of poor quality;
they were very moist and poorly formed, with the con-
sistency of putty or porridge. Moist feces, which never-
theless had some definite form, were scored as 3.5.
Score 3 represented feces of good quality that were
slightly moist. Ideal feces were those that could easily be
picked up and left no stain (scores 2.5 and 2). In addi-
tion, the owners evaluated daily the severity of the fol-
lowing clinical signs: alertness (normal or reduced),
appetite (normal, reduced, or considerably reduced),
borborygmus (no, occasionally, or often), flatulence (no,
occasionally, or often), and vomiting (no, occasionally,
or often). If diarrhea did not reappear during the two-
month follow-up, the dogs were released from the study
(Figure 1).
Treatment period
Dogs with reappearance of diarrhea (fecal consistency
score ≥4) went through the same procedures as in the
initial examination, excluding the gastroduodenoscopy.
In addition, a fresh fecal sample was collected manually
from the rectum and cultured at the Veterinary Bacter-
iology, Research Department of the Finnish Food Safety
Authority, Helsinki, Finland, for Yersinia spp., Salmo-
nella spp., Campylobacter spp., Clostridium difficile, and
Clostridium perfringens. Either tylosin or placebo treat-
ment was then initiated. Both the investigator and
owner were blinded to treatment. Information about
whether the bottle contained tylosin tartrate or placebo
was indicated in a randomization list kept by an external
study manager. One-third of the bottles contained pla-
cebo and two-thirds tylosin tartrate. The test products
were tylosin tartrate (Tylosin tartrate tablets, University
Pharmacy, Helsinki, Finland) tablets 120 mg and 240
mg containing 100 mg and 200 mg of tylosin, respec-
tively, and placebo tablets containing microcrystalline
cellulose (Microcrystalline cellulose tablets, University
Pharmacy, Helsinki, Finland). The tablets were identical
visually, as were the labels on the bottles.
On day 3 of the treatment period, the owner was con-
tacted by telephone to determine the clinical condition
of the dog. If the dog had excessive diarrhea and the
clinical condition was poor, the dog was released from
the study and treated accordingly.
For dogs continuing the protocol, on day 7 of the
treatment period, a physical examination, rectal palpa-
tion, and evaluation of fecal consistency according to
the guidelines were performed and the treatment code
broken. To evaluate whether the treatment was effective,
the mean value of the fecal consistency scores during
the fifth, sixth, and seventh days of treatment was calcu-
lated. A responder was defined as having a mean fecal
consistency score ≤3.0, and a nonresponder as having a
mean fecal consistency score >3.0. The owners were
unaware of these definitions. In dogs that did not
r e s p o n dt o2 5m g / k gt y l o s i no n c ead a y ,t h ed o s ew a s
doubled (25 mg/kg tylosin twice a day for seven days).
Those not responding to the placebo treatment were
given 25 mg/kg tylosin once a day for seven days. Pla-
cebo responders were released from the study (Figure 1).
Statistical methods
To test for differences between the tylosin and the pla-
cebo group in the proportion of responders, Pearson’s
Chi-squared test and Fisher’s exact test were applied.
The level of significance was set at p < 0.05. Statistical
analyses were performed using SPSS 14.0 for Windows.
Results
Seventy-one suspected TRD dogs (41 males, 30
females) were enrolled in the study. The dogs con-
sisted of 33 different breeds, the most common breeds
being Rough Collie (n = 10), German Shepherd Dog
(n = 7), and Golden Retriever (n = 6). Dogs’ ages at
the time of the initial examination ranged from six
months to 13 years (median three years and four
months). The weight of the dogs ranged from 6.2 kg
to 67.2 kg (median 25.5 kg).
At the initial examination, all dogs were randomly
allocated into a tylosin treatment group (n = 47) or a
placebo group (n = 24). However, ten dogs did not fulfill
the selection criteria and were excluded from the study.
Sixty-one dogs met the selection criteria and started the
two-month follow-up. In 34 dogs, diarrhea did not recur
during the follow-up period, and they were released
from the study (Figure 2). In 27/61 dogs (43.3%), diar-
rhea recurred, on a median of day 8 (range 1-60) of the
follow-up, and they started the prospective treatment
period. At the time of commencement of the treatment
period, the tylosin group comprised 20 dogs and the
placebo group 7 dogs.
The 27 dogs starting the treatment period consisted of
19 different breeds, the most common breeds being
Golden Retriever (n = 5), German Shepherd Dog (n =
3), and Rough Collie (n = 3). Both the tylosin and pla-
cebo groups contained more males than females. The
age of the dogs ranged from six months to 11 years
(median three years). The weight of the dogs ranged
from 8.2 kg to 64.0 kg (median 24.5 kg).
In the 27 dogs starting the treatment period, the clini-
cal signs during earlier diarrhea episodes were similar in
dogs of both groups (Table 1). Diarrhea was mainly
watery or pulpy, and blood or mucus was often present.
The frequency of defecation was increased in 81% of the
dogs and weight loss was present in an equal propor-
tion. Vomiting occurred in 11/27 dogs. In more than
half of the dogs, diarrhea signs started at a young age
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been discontinued at least twice, and diarrhea had
recurred in 55% within 20 days of discontinuation. In all
dogs, diarrhea had ceased within two days of the start of
tylosin treatment.
In dogs starting the treatment period, CBC and serum
biochemical profile were within the reference range or
there were only minor changes at the initial examina-
tion. Serum cobalamin concentrations were below the
reference range in eight dogs, six in the tylosin and two
in the placebo group. Serum folate concentrations were
below the reference range in six dogs, five in the tylosin
and one in the placebo group. Seven dogs, all in the
tylosin group, had serum folate concentrations above
the reference range.
There were no abnormal findings in urine samples.
Fecal samples of six dogs, four in the tylosin group, all
being responders, and two in the placebo group, one
being a responder and one a nonresponder, were
positive for Giardia spp. One dog had hookworms and
one had isospora, both in the tylosin group.
Gastroduodenoscopy was performed on 19/20 dogs of
the tylosin group and 5/7 dogs of the placebo group. In
three dogs, gastroduodenoscopy was not performed at
the owner’s request. In one dog, the duodenum was not
reached. Table 2 displays the histopathological scoring
of duodenal changes in endoscopically taken mucosal
biopsies in dogs receiving either tylosin or placebo. The
category “other types of inflammation” included three
dogs with mild to moderate neutrophilic inflammation
and one dog with lymphohistiocytic inflammation. Mild
morphological changes were found in 12 biopsies, all of
which showed mild or moderate inflammation and were
therefore considered part of the inflammatory reaction.
Due to the small number of dogs in the placebo group,
no statistical analysis was possible between the groups
concerning the results of the histopathological examina-
tion of the biopsies.
Figure 2 Results of enrollment, allocation, and response to treatment of suspected TRD dogs.
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Page 5 of 10Table 1 Clinical history prior to the study of the 27 dogs starting the treatment period.
Tylosin group Placebo group
Responder (n = 17) Nonresponder (n = 3) Responder (n = 2) Nonresponder (n = 5)
Diet at initial examination
Commercial 2 2 2
Home-made 6 1 1 1
Both 9 1 2
Commercial diet
Dry 8 1 2
Canned 1
Both 2 1 1 2
Signs during diarrhea episodes:
Appetite
Normal 11
Moderately decreased 1 2 1 2
Severely decreased 3 1 3
Increased 2 1
Weight loss
Moderate 5 1 3
Mild 8 2 1 2
None 3 1
No answer 1
Vomiting
Typical 2 2 2
Fairly typical 3 1 1
None 11 1 1 2
No answer 1
Borborygmus
Typical 5 2 1 3
Fairly typical 6 1 1 1
None 6 1
Flatulence
Typical 9 1 1 3
Fairly typical 1 1
None 7 1 1 2
Fecal consistency
Watery 15 3 1 4
Bloody 7 4
Mucus 9 1 1 5
Pulpy 9 2 2 2
Frequency of defecation
Increased 14 2 2 4
Normal 2 1 1
No answer 1
Age in years when diarrhea began
<1 6 2 1 4
1-2 3 1
3-7 7 1 1
>7 1
Tylosin discontinued n times prior to
study
01 2
13 1 1 2
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ment period started, a physical examination was per-
formed and blood and fecal samples were taken. None
of the dogs was in poor clinical condition, but five dogs
had decreased appetite. Four dogs were slightly apathetic
at the beginning of the diarrhea. Flatulence was present
in 14 dogs. Eleven dogs suffered from borborygmus and
five from vomiting. The results from the blood samples
did not differ from those at the initial examination.
Giardia spp. or other endoparasites were not detected
in any of the fecal samples.
In the bacteriological analysis, fecal samples were posi-
tive in 18/27 dogs for Clostridium perfringens (nine tylo-
sin responders, three tylosin nonresponders, two
placebo responders, four placebo nonresponders), in 2/
27 dogs for Campylobacter jejuni (one placebo respon-
der, one nonresponder), in 1/27 dogs for Yersinia enter-
ocolitica (placebo nonresponder), and in 1/27 dogs for
Salmonella Typhimurium (tylosin responder). In two
dogs, two pathogenic bacteria were detected simulta-
neously. No difference was seen in the bacteriological
culture of Clostridium perfringens between the respon-
ders and nonresponders (Pearson’s Chi-squared test p =
0.136, Fisher’s exact test two-sided p = 0.201) or
between the tylosin and placebo group (Pearson’sC h i -
squared test p = 0.214, Fisher’s exact test two-sided p =
0.363).
In the tylosin group, 17/20 dogs responded to treat-
ment (Figure 2), with a mean fecal score over the last
three treatment days of 2.47 (range 1.83-2.93). Three
dogs did not respond to the tylosin therapy, with a
mean fecal score over the last three treatment days of
3.64 (range 3.41-3.86). After the treatment period, one
of these three dogs was removed due to protocol viola-
tion (Figure 2).
In the placebo group, 2/7 dogs responded to placebo
treatment (Figure 2), with a mean fecal score over the
last three treatment days of 2.68 (range 2.67-2.70).
These dogs were released from the study. Five dogs did
not respond to the placebo treatment, with a mean fecal
score over the last three treatment days of 3.89 (range
3.19-5.00). One of them was removed after the
Table 2 Histopathological scoring of biopsies according to responders and nonresponders in the tylosin and placebo
groups.
Tylosin group Placebo group
Responder (n = 16) Nonresponder (n = 3) Responder (n = 2) Nonresponder (n = 2)
Type of inflammation
No changes 3 0 0 1
Lymphoplasmacytic 9 2 1 0
Eosinophilic 2 1 0 0
Other 2 0 1 1
Grade of inflammation
No changes 3 0 0 1
Mild 9 1 1 1
Moderate 4 1 1 0
Severe 0 1 0 0
Table 1 Clinical history prior to the study of the 27 dogs starting the treatment period. (Continued)
2-4 10 1
>4 3 3
Cessation of diarrhea after start of
tylosin treatment
1 day 10 2 5
2 days 7 1 2
Recurrence of diarrhea after tylosin
discontinuation
< 10 days 5 2 1 1
10-20 days 4 2
> 20 days 2 1
Irregular 4 1 1
No recurrence 2 1
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Page 7 of 10treatment period for noncompliance. The four remain-
ing nonresponders were subsequently given tylosin 25
mg/kg once daily. Three of these dogs responded; the
mean fecal score over the last three treatment days was
2.36 (range 2.14-2.50). One dog did not respond, with a
mean fecal score over the last three treatment days of
3.58 (Figure 2).
Two nonresponders in the tylosin group and one in
the placebo group that failed to respond to tylosin 25
mg/kg once daily subsequently received tylosin 25 mg/
kg twice daily (Figure 2). None responded to the double
dose, the mean fecal score over the last three treatment
days being 3.48 (3.29-3.67).
The proportion of dogs with a fecal consistency score
of three or less was 85% (17/20) in the tylosin group
and 29% (2/7) in the placebo group. This difference is
significant (Pearson’s Chi-squared test p = 0.0049 and
Fisher’s exact test two-sided, p = 0.0114).
Overall, 20/24 dogs (83%) responded to tylosin ther-
apy and 4/24 (17%) did not (Figure 2).
Discussion
Tylosin has been widely used to treat canine intermit-
tent and chronic diarrhea, although only a few studies
have been published about the effect of tylosin on dogs
with diarrhea [1,2,7,8]. None of the studies cited was
controlled with a placebo. To provide more evidence-
based research on tylosin, we performed a placebo-con-
trolled, randomized, double-blinded, prospective clinical
trial. Of the 24 suspected TRD dogs treated with tylosin,
20 were responders. The outcome of these dogs was in
agreement with owners’ earlier experiences. However, in
four dogs diarrhea did not stop with tylosin medication,
although based on information from the owners it had
previously helped to control diarrhea. At this point,
w h e nt h ee t i o l o g yo fT R Di su n c l e a r ,i ti sp o s s i b l et h a t
the reasons for the diarrhea in these dogs differed from
the previous times.
Our trial showed that the effectiveness of tylosin on
fecal consistency of dogs with suspected TRD is signifi-
cantly higher than that of placebo treatment. In 85% of
dogs receiving tylosin, diarrhea ceased within a seven-
day treatment period, in contrast to a response rate of
29% in dogs receiving placebo. Interestingly, the effect
of tylosin on these dogs is similar to that reported in a
study with rhesus macaques suffering from chronic diar-
rhea and failing to respond to antibiotics other than
tylosin [9].
In healthcare, efficacy is usually defined as the capa-
city for beneficial change of a given intervention and
not only as a curative effect. Based on our results, tylo-
sin is effective in treating chronic diarrhea in dogs.
However, as the etiology of TRD remains obscure, we
do not know whether tylosin is a symptomatic or
curative treatment. After discontinuation of tylosin
treatment, diarrhea recurs in many dogs, and thus, tylo-
sin could be considered a symptomatic treatment in
these dogs. However, our findings are in accordance
with previous studies [1,2] and anecdotal reports in that
not all dogs develop diarrhea after stopping the tylosin
course; in these patients, tylosin could be seen as a cura-
tive treatment.
To our knowledge, no other double-blinded, placebo-
controlled studies on dogs with diarrhea exist in the
literature. Performing this kind of a trial with client-
owned diarrhea patients is demanding. The most diffi-
cult part is ensuring that at the start of the trial both
placebo and active treatment groups are as homoge-
neous as possible. Unfortunately, dogs suffering from
d i a r r h e au s u a l l yc o m p r i s eav ery heterogeneous group
of patients. Assuring the similarity of both groups con-
cerning clinical history, clinical signs, and physical
examination is therefore challenging. Using only dogs
with suspected TRD, based on previous outcomes of
therapeutic trials with tylosin, provided a similar start-
ing point for all dogs at the beginning of the trial. The
suspected TRD dogs participating in this study repre-
sented dogs that had received at least one empiric tylo-
sin treatment due to recurrent diarrhea during the last
four weeks prior to study enrollment and the owners
had the impression that tylosin had had a positive
effect on their dogs’ diarrhea. Furthermore, the
absence of diarrhea at the beginning of the trial was
set as one selection criterion. Based on the initial
examination, we could not predict whether the diar-
rhea would reappear in follow-up or whether the dog
would respond to tylosin within the treatment period.
Using dogs that have previously received tylosin for
the treatment of their diarrhea is a reliable regime to
explore whether the anecdotal reports of owners’ ear-
lier positive impressions of the tylosin therapy in treat-
ing their dogs’ diarrhea are true.
Difficulties in this kind of trial are encountered also in
keeping owners committed to the study protocol while
their pet suffers from diarrhea longer than necessary.
Skewed randomization strategies, which allow more
patients to enter one group versus another, are a recog-
nized approach when there is an ethical risk of severe
clinical signs in patients not receiving the active treat-
ment [10-12]. The allocation ratio of 2:1 minimized
inconvenience and discomfort of patients not receiving
the active treatment and having severe clinical signs.
Excessive diarrhea can result in a patient’s poor clinical
condition due to severe dehydration and electrolyte and
acid-base imbalances. Fortunately, none of the dogs
enrolled in our study had such excessive diarrhea that
the trial had to be interrupted because of inconvenience
to the owner. In no case did the clinical condition of
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point and release from the trial were essential.
The dogs were randomized into the placebo and tylo-
sin groups already at the initial examination, when the
dogs had no clinical signs of diarrhea. This was done
because we assumed, based on a previous study on TRD
[1], that during the two-month follow-up diarrhea
would reappear in almost every dog enrolled in the
study and therefore in similar numbers of dogs in both
groups. However, diarrhea reappeared in only every sec-
ond dog enrolled in the study and, by chance, less fre-
quently in the dogs assigned to the placebo group. For
this reason, the anticipated distribution to the different
t r e a t m e n tg r o u p sd i dn o tc o m et of r u i t i o n ,a n da tt h e
time of the treatment the placebo group comprised
fewer dogs than expected. In retrospect, randomization
to the placebo and tylosin groups should have taken
place at the time-point when diarrhea started and the
treatment period began.
Concerning the lower recurrence rate of diarrhea in
the dogs enrolled in our study, it is pertinent that we
included also dogs that had received only one successful
tylosin course due to recurrent diarrhea of unknown
origin, in contrast to previous studies [1,2], which con-
sisted of dogs receiving several tylosin courses and had
a repeated response. Our study also differed from these
earlier studies in that we investigated a far higher num-
ber of dogs, which can lead to speculation that we may
have included patients with either a broader variety of
etiologies or differing severities of the same disorder,
resulting in different responses to tylosin. It remains
unclear why certain dogs do not develop diarrhea again
after discontinuing tylosin.
The length of the treatment period was set at seven
days because previous studies have shown that with
tylosin treatment diarrhea stops within a few days [1,2].
No official dose recommendations exist for tylosin in
the treatment of canine enteropathies. The dose of 25
mg/kg once daily used in the treatment period here is
similar to that suggested in the literature [13]. Based on
our results, this dose appears sufficient, and no addi-
tional benefit was gained by increasing it. None of the
nonresponders subsequently receiving tylosin 25 mg/kg
twice daily responded to the double dose.
T h ec l i n i c a lh i s t o r yo fs u s pected TRD dogs was simi-
lar to that reported in a smaller study consisting of 14
dogs [1]. The dogs in our study were young or middle-
aged and belonged mainly to medium-sized and giant
breeds, but no breed predilection was found. The clini-
cal signs suggested the diarrhea was more often large
bowel diarrhea, as in more than two-thirds of the dogs
the frequency of defecation had increased and about
half of the dogs had mucus and bloody feces. The histo-
pathologic changes in the mucosal biopsies varied
between the different dogs, but due to the small number
of dogs in the placebo group, no statistical analysis was
possible between the groups.
No changes specific to TRD were detected in the his-
topathological examinations, and therefore, one could
not based on the histopathology predict whether the
dog would respond to tylosin treatment or not. At the
initial examination, no reason for the diarrhea in the
dogs was found. The dogs could thus be referred to as
dogs with diarrhea of unknown origin.
Fecal samples were cultured when the diarrhea
started, and 20/27 samples were positive for some of the
most common enteropathogenic bacteria. The positive
findings were distributed across responders and nonre-
sponders in both treatment groups, indicating that these
pathogenic bacteria are unlikely to be the causative fac-
tors for the diarrhea in TRD dogs. Enteropathogenic
bacteria have been detected also in the fecal cultures of
clinically healthy dogs [3] and dogs with TRD [1,2].
Fecal samples of six dogs were Giardia-positive at the
time of the initial examination. All of these dogs were
negative for Giardia after fenbendazole medication when
the control sample was taken during diarrhea recurrence
in the follow-up period. The highest sensitivity and spe-
cificity for Giardia spp. were detected for the immu-
noassay we utilized in our trial, when three different
methods were compared [14]. We can therefore con-
clude that Giardia spp. is not a possible etiologic agent
for the diarrhea in these dogs.
Different antibiotics have been recommended for the
treatment of canine chronic and intermittent diarrhea
[15]. However, no study has been carried out to deter-
mine which antibiotic is the most effective in treating
chronic diarrhea patients. In one study with six dogs,
tylosin was found to be superior to trimethoprim sulfo-
namide, doxycycline, or metronidazole [2]. No apparent
tylosin-associated clinical side-effects have been
described. No clinical adverse events occurred during
our trial. Interestingly, the effect of tylosin has been
reported not to diminish even with longer or repeated
treatment periods [13]. Long-term usage of antibiotics
typically contributes to the development of microbial
resistance to antibiotics, and getting a positive effect
when the same antibiotic substance is used repeatedly
to treat the same disease in the same individual is diffi-
cult. Tylosin, as all antibiotics, causes resistance in the
intestinal bacterial flora. This is a significant problem
and chronic diarrhea in dogs should preferably be trea-
ted without long-term antibiotic administration. Indis-
criminate use of antibiotics should be avoided, and in
patients with chronic diarrhea every effort should be
made to achieve a diagnosis that enables a specific
therapy. An extensive work-up to rule out systemic
disorders with secondary diarrhea, endoparasites, and
Kilpinen et al. Acta Veterinaria Scandinavica 2011, 53:26
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ing a therapeutic trial with tylosin.
Conclusions
Our findings indicate that tylosin is effective in treating
recurrent diarrhea in dogs. The dose of 25 mg/kg once
daily seems sufficient. No changes specific to TRD were
detected in the examinations. Several different underly-
ing reasons may exist for TRD. Currently, it is difficult
to predict which patients suffering from gastrointestinal
disease will benefit from tylosin medication. The only
way of knowing appears to be a therapeutic trial. The
exact mechanism of action of tylosin is unknown and
further studies are needed to explore why tylosin has a
favorable effect in the treatment of canine chronic
enteropathies.
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